Correct. A clinical trial is just that. Designed to maximise collectable data a human clinical trial helps to establish efficacy and toxicity outcomes without lethal effect. Variation of dosage to achieve optimum outcome is normal. The optimum adaptive dosage response achievable is then plotted to produce a design that can hopefully then be commercially replicated. My opinion only of course!
Ann: Imugene to present at 2024 Cholangiocarcinoma Conference, page-189
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $395.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $1.766M | 32.04M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 686758 | 5.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.8¢ | 1801664 | 24 |
View Market Depth
| Last trade - 13.36pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |